Harvard Bioscience, Inc. (HBIO)
After hours:
| Previous close | 2.4600 |
| Open | 2.4800 |
| Bid | 2.3500 x 100 |
| Ask | 2.4400 x 100 |
| Day's range | 2.3850 - 2.5113 |
| 52-week range | 2.3800 - 5.5600 |
| Volume | |
| Avg. volume | 110,287 |
| Market cap | 104.666M |
| Beta (5Y monthly) | 1.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings date | 05 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.25 |
GlobeNewswireHarvard Bioscience to Showcase Innovative Technologies at Society for Neuroscience (SfN) Annual Meeting 2024
New products complement an already extensive range of products enabling fundamental advancements in neuroscience researchHOLLISTON, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) 2024 Annual Meeting being held October 5 - 9 in Chicago. Cutting-edge innovations on display include the revolutionary new Mesh MEA™ microelectrode array system, the SoHo™ imp
Simply Wall St.The past three years for Harvard Bioscience (NASDAQ:HBIO) investors has not been profitable
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
- GlobeNewswire
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting
Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy developmentHOLLISTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Safety Pharmacology Society (SPS) Annual Meeting being held from September 22-25, 2024, in San Diego. DSI™ Ponemah™ Data Management Platform Provides Integrated Preclinical Sol
